Arkolith/Insider Trading/PTGX/Form 4

Patel Dinesh V PH D

President and CEO, DirectorProtagonist Therapeutics, Inc (PTGX) · full profile →Form 4 · filed Jan 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4.1M
Net Open-Market Flow
-$4.1M
Transactions
13
9 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 27, 2026Sell(S)4K$83.19$338K575K
Jan 27, 2026Option exercise(M)4K$21.58$88K579K
Jan 26, 2026Sell(S)11K$84.00$898K575K
Jan 26, 2026Option exercise(M)14K$21.58$307K589K
Jan 26, 2026Sell(S)14K$84.05$1.2M575K
Jan 26, 2026Option exercise(M)11K$4.21$45K585K
Jan 23, 2026Option exercise(M)19K$4.21$81K594K
Jan 23, 2026Gift(G)6K—$0575K
Jan 23, 2026Sell(S)19K$84.59$1.6M575K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 27, 2026Option exercise(M)4K—$0300K
Jan 26, 2026Option exercise(M)14K—$0304K
Jan 26, 2026Option exercise(M)11K—$00
Jan 23, 2026Option exercise(M)19K—$011K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
G
Gift

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-007129) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML